Support and Resistance Basics
What is MACD and how to read it?
How RSI can help?
Stock Summary
Top Correlated Resources
ACCD
Top 10 Correlated ETFs
ACCD
Top 10 Correlated Stocks
ACCD
In the News
Here's Why Accolade Shares Are Trading Higher Today
Needham analyst Ryan MacDonald reiterated a Buy rating on Accolade, Inc (NASDAQ: ACCD) with a price target of $12. Following a problematic 4QF22, he noted that Accolade bounced back nicely in 1QF23 as the company beat management's initial outlook for.
Accolade Moves Higher But Growth Is Slowing
Accolade (NASDAQ: ACCD) is certainly an interesting play on the health care space providing business and employee services geared toward helping clients navigate the cumbersome health benefits arena. The pandemic helped boost the company's business and has on track to continue growing but there is a fly in the ointment.
Accolade, Inc. (ACCD) CEO Rajeev Singh on Q1 2023 Results - Earnings Call Transcript
Accolade, Inc. (NASDAQ:ACCD ) Q1 2023 Earnings Conference Call June 30, 2022 4:30 PM ET Company Representatives Rajeev Singh - Chief Executive Officer Steve Barnes - Chief Financial Officer Shantanu Nundy - Chief Medical Officer Todd Friedman - Senior Vice President of Investor Relations Conference Call Participants Ryan Daniels - William Blair Glen Santangelo - Jefferies Richard Close - Canaccord Genuity Michael Cherny - Bank of America. Cindy Motz - Goldman Sachs Jonathan Yong - Credit Suisse Craig Hettenbach - Morgan Stanley Jeff Garro - Piper Sandler David Larsen - BTIG Ryan MacDonald - Needham Stephanie Davis - SVB Securities Stan Berenshteyn - Wells Fargo Dev Weerasuriya - Berenberg Sandy Draper - Guggenheim Operator Good day!
Accolade (ACCD) Reports Q1 Loss, Tops Revenue Estimates
Accolade (ACCD) delivered earnings and revenue surprises of 45.21% and 3.80%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?
Accolade (ACCD) Stock Jumps 7.2%: Will It Continue to Soar?
Accolade (ACCD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Accolade Announces Participation in June Investor Conferences
SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will participate in the following upcoming investor conferences. A webcast and replay of each event will be available at ir.accolade.com.
Accolade Announces Participation in May Investor Conferences
SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will participate in the following upcoming investor conferences. A webcast and replay of each event will be available at ir.accolade.com.
Why Is Accolade (ACCD) Stock Up Today?
Today, investors in Accolade and ACCD stock have something to cheer, following a rather dismal end to last week. The post Why Is Accolade (ACCD) Stock Up Today?
Accolade Stock Rebounds. It's Upgraded on More Balanced Risk-Reward.
Wells Fargo upgrades Accolade to Equal Weight from Underweight, saying the stock's current price point creates a more balanced risk-and-reward profile.
Why Are Accolade Shares Down Over 40% Today
Accolade Inc (NASDAQ: ACCD) shares plunged almost 50% after disappointing Q4 FY22 earnings and FY23 guidance. Q4 FY22 revenue increased 58% Y/Y to $93.8 million, beating the consensus of $91.57 million.
Financial details
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-02-28
| Metric | History | 2021-02-28 | 2022-02-28 |
|---|---|---|---|
| Revenue per share | 5.8 | 4.86 | |
| Net income per share | -1.72 | -1.93 | |
| Operating cash flow per share | -0.86 | -0.98 | |
| Free cash flow per share | -0.94 | -1.03 | |
| Cash per share | 14.77 | 5.73 | |
| Book value per share | 13.31 | 13.41 | |
| Tangible book value per share | 13.15 | 0.52 | |
| Share holders equity per share | 13.31 | 13.41 | |
| Interest debt per share | 0.13 | 5.06 | |
| Market cap | 1.31B | 1.15B | |
| Enterprise value | 872.23M | 1.1B | |
| P/E ratio | -25.79 | -9.32 | |
| Price to sales ratio | 7.67 | 3.7 | |
| POCF ratio | -51.76 | -18.4 | |
| PFCF ratio | -47.33 | -17.4 | |
| P/B Ratio | 3.34 | 1.34 | |
| PTB ratio | 3.34 | 1.34 | |
| EV to sales | 5.12 | 3.55 | |
| Enterprise value over EBITDA | -22.53 | -13.23 | |
| EV to operating cash flow | -34.57 | -17.67 | |
| EV to free cash flow | -31.61 | -16.7 | |
| Earnings yield | -0.04 | -0.11 | |
| Free cash flow yield | -0.02 | -0.06 | |
| Debt to equity | 0 | 0.37 | |
| Debt to assets | 0.18 | 0.33 | |
| Net debt to EBITDA | 11.21 | 0.55 | |
| Current ratio | 5.74 | 3.66 | |
| Interest coverage | -12.56 | -43.28 | |
| Income quality | 0.5 | 0.51 | |
| Dividend Yield | 0 | 0 | |
| Payout ratio | 0 | 0 | |
| Sales general and administrative to revenue | 0.19 | 0.32 | |
| Research and developement to revenue | 0.29 | 0.27 | |
| Intangibles to total assets | 0.01 | 0.64 | |
| Capex to operating cash flow | 0.09 | 0.06 | |
| Capex to revenue | -0.01 | -0.01 | |
| Capex to depreciation | -0.29 | -0.08 | |
| Stock based compensation to revenue | 0.06 | 0.24 | |
| Graham number | 22.72 | 24.13 | |
| ROIC | -0.12 | -0.11 | |
| Return on tangible assets | -0.11 | -0.27 | |
| Graham Net | 12.19 | -0.64 | |
| Working capital | 374.91M | 297.38M | |
| Tangible asset value | 386.23M | 33.21M | |
| Net current asset value | 369.32M | -20.6M | |
| Invested capital | 0 | 0.37 | |
| Average receivables | 11.84M | 21.32M | |
| Average payables | 7.39M | 7.61M | |
| Average inventory | 0 | 0 | |
| Days sales outstanding | 25.36 | 36.26 | |
| Days payables outstanding | 28.8 | 16.92 | |
| Days of inventory on hand | 0 | 0 | |
| Receivables turnover | 14.39 | 10.07 | |
| Payables turnover | 12.68 | 21.57 | |
| Inventory turnover | 0 | 0 | |
| ROE | -0.13 | -0.14 | |
| Capex per share | -0.08 | -0.06 |
Quarterly Fundamentals Overview
Last date of statement is 2022-05-31 for Q1
| Metric | History | 2021-05-31 | 2021-08-31 | 2021-11-30 | 2022-02-28 | 2022-05-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.02 | 1.14 | 1.28 | 1.39 | 1.23 | |
| Net income per share | -0.84 | -0.97 | 0.34 | -0.51 | -4.92 | |
| Operating cash flow per share | -0.47 | -0.17 | -0.33 | -0.03 | -0.44 | |
| Free cash flow per share | -0.49 | -0.19 | -0.34 | -0.04 | -0.46 | |
| Cash per share | 7.3 | 5.96 | 5.59 | 5.44 | 4.81 | |
| Book value per share | 7.5 | 11.39 | 12.06 | 12.72 | 7.66 | |
| Tangible book value per share | 0.33 | -1.51 | -0.7 | 0.49 | 0.32 | |
| Share holders equity per share | 7.5 | 11.39 | 12.06 | 12.72 | 7.66 | |
| Interest debt per share | 4.81 | 4.36 | 4.3 | 4.76 | 4.61 | |
| Market cap | 2.97B | 3.05B | 1.68B | 1.21B | 447.72M | |
| Enterprise value | 2.93B | 2.95B | 1.59B | 1.16B | 432.74M | |
| P/E ratio | -15.27 | -12.23 | 18.66 | -8.75 | -0.33 | |
| Price to sales ratio | 49.96 | 41.64 | 20.12 | 12.91 | 5.23 | |
| POCF ratio | -107.71 | -276.65 | -78.39 | -529.81 | -14.7 | |
| PFCF ratio | -105.04 | -248.94 | -74.94 | -405.39 | -14.11 | |
| P/B Ratio | 6.8 | 4.16 | 2.13 | 1.41 | 0.84 | |
| PTB ratio | 6.8 | 4.16 | 2.13 | 1.41 | 0.84 | |
| EV to sales | 49.19 | 40.22 | 19.1 | 12.41 | 5.06 | |
| Enterprise value over EBITDA | -74.37 | -46.48 | 42.13 | -63.66 | -1.29 | |
| EV to operating cash flow | -106.04 | -267.21 | -74.39 | -509.62 | -14.21 | |
| EV to free cash flow | -103.41 | -240.44 | -71.11 | -389.94 | -13.64 | |
| Earnings yield | -0.02 | -0.02 | 0.01 | -0.03 | -0.77 | |
| Free cash flow yield | -0.01 | 0 | -0.01 | 0 | -0.07 | |
| Debt to equity | 0.64 | 0.38 | 0.36 | 0.37 | 0.59 | |
| Debt to assets | 0.51 | 0.42 | 0.38 | 0.33 | 0.43 | |
| Net debt to EBITDA | 1.17 | 1.64 | -2.27 | 2.52 | 0.04 | |
| Current ratio | 2.71 | 1.67 | 2.21 | 3.66 | 3.95 | |
| Interest coverage | -77.69 | -95.93 | 35.73 | -38.82 | -545.8 | |
| Income quality | 0.57 | 0.18 | -0.95 | 0.07 | 0.09 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.55 | 0.36 | 0.26 | 0.31 | 0.24 | |
| Research and developement to revenue | 0.27 | 0.31 | 0.27 | 0.24 | 0.31 | |
| Intangibles to total assets | 0.47 | 0.65 | 0.66 | 0.64 | 0.54 | |
| Capex to operating cash flow | 0.03 | 0.11 | 0.05 | 0.31 | 0.04 | |
| Capex to revenue | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | |
| Capex to depreciation | -0.08 | -0.11 | -0.09 | -0.06 | -0.11 | |
| Stock based compensation to revenue | 0.13 | 0.27 | 0.22 | 0.29 | 0.23 | |
| Graham number | 11.88 | 15.75 | 9.66 | 12.12 | 29.12 | |
| ROIC | -0.07 | -0.07 | 0.02 | -0.03 | -0.41 | |
| Return on tangible assets | -0.1 | -0.14 | 0.05 | -0.07 | -0.79 | |
| Graham Net | -0.26 | -2.15 | -1.36 | -0.61 | -0.76 | |
| Working capital | 285.97M | 168.21M | 222.95M | 297.38M | 282.09M | |
| Tangible asset value | 19.43M | -97.27M | -46.01M | 33.21M | 22M | |
| Net current asset value | -926K | -118.63M | -67.1M | -20.6M | -32.38M | |
| Invested capital | 0.64 | 0.38 | 0.36 | 0.37 | 0.6 | |
| Average receivables | 24.41M | 24.76M | 28.35M | 30.8M | 29.64M | |
| Average payables | 7.46M | 8.27M | 6.79M | 7.84M | 7.81M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 27.25 | 22.99 | 27.94 | 29.57 | 29.97 | |
| Days payables outstanding | 17.75 | 17.65 | 11.45 | 16.18 | 14.7 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 3.3 | 3.91 | 3.22 | 3.04 | 3 | |
| Payables turnover | 5.07 | 5.1 | 7.86 | 5.56 | 6.12 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.11 | -0.09 | 0.03 | -0.04 | -0.64 | |
| Capex per share | -0.01 | -0.02 | -0.02 | -0.01 | -0.02 |
Company Profile
- Volume Average 1.31M
- Market Capitalization 826.74M
- Employee 2.35K
- CEO Mr. J. Michael Cline
- Headquarters Plymouth Meeting,PA,US
- IPO Date 2020-07-02
-
Website
https://www.accolade.com 
Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.
